MIR — Mirion Technologies, Inc.

Mirion Technologies Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $277.4 million, up 9% year-over-year (YoY), with over half of the growth attributed to M&A (CertRec and Paragon).
• Organic Growth: 0.5% in Q4, impacted by tough comps from the previous year.
• Full-Year Revenue: $925.4 million, a 7.5% increase from 2024, with more than half of the growth being organic.
• Adjusted EBITDA: $227.9 million for the full year, up 12% YoY, with margins expanding by 90 basis points.
• Adjusted EPS: $0.46, a 12% increase YoY despite a higher share count due to convertible notes and equity raises.
• Free Cash Flow: $131 million for the year, doubling 2024's performance with a conversion rate of 57%.

2. Strategic Updates and Business Highlights

• Record Orders: Total orders exceeded $1 billion in 2025, a 26% increase from 2024, driven by strong demand in the nuclear power market.
• Acquisitions: Successful integration of CertRec and Paragon Energy Solutions, enhancing Mirion's presence in the North American nuclear power market and expanding its capabilities in the SMR (Small Modular Reactor) space.
• Market Dynamics: Continued focus on the nuclear power sector, which now accounts for approximately 40% of total revenue. The company is well-positioned to capitalize on life extensions and modernization of existing nuclear facilities.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected to grow between 22-24%, with organic growth projected at 5-7%.
• Adjusted EBITDA Guidance: Anticipated between $285 million and $300 million, with margins expected to expand to 25-26%.
• Free Cash Flow: Projected to be between $155 million and $175 million, reflecting ongoing improvements in earnings and capital structure.
• Adjusted EPS: Expected to range from $0.50 to $0.57, including stock-based compensation for the first time.

4. Bad News, Challenges, or Points of Concern

• Headwinds in Medical Segment: The medical segment faced challenges with a 6% decline in nuclear medicine orders and a 3.5% decline in Q4 revenue, attributed to tough comps and sluggish market conditions.
• Government Shutdown Impact: The lengthy government shutdown negatively affected orders in the labs and research segment, which is expected to take time to normalize.
• Dilutive Impact from Acquisitions: The Paragon acquisition is expected to have a dilutive effect on margins in the near term, which may impact overall profitability.

5. Notable Q&A Insights

• Large Opportunity Pipeline: The pipeline for large projects is now over $400 million, with a strong right to win, although timing remains uncertain.
• Medical Segment Recovery: Management expressed cautious optimism for a rebound in the medical segment, particularly in Q2 2026, driven by improved market conditions in Europe and China.
• SMR Growth Potential: While SMR orders are currently a small percentage of total revenue, the company sees significant growth potential in this area, with ongoing engagement with over 20 SMR developers.
• AI Integration: The company is focusing on leveraging AI to improve operational efficiency and customer engagement, with ongoing development of internal applications.

Overall, Mirion Technologies demonstrated strong performance in 2025, driven by strategic acquisitions and a robust nuclear power market, while facing challenges in the medical segment and external market conditions. The outlook for 2026 remains positive, with expectations for continued growth and margin expansion.